In 229 randomised adults with primary CNS lymphoma responding to MATRix induction, thiotepa-based high-dose chemotherapy with ASCT improved 3-year PFS vs R-DeVIC (78% vs 51%; HR 0·43), with more adverse events and 5 vs 2 fatal SAEs.
RCTn = 230
Illerhaus et al. High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial